The University of Chicago Header Logo

Connection

Rochelle Naylor to Humans

Back to Details
This is a "connection" page, showing publications Rochelle Naylor has written about Humans.
Rochelle Naylor
Connection Strength
0.291
Humans
  1. The Do-It-Yourself Artificial Pancreas. Pediatr Ann. 2021 Jul; 50(7):e304-e307.
    View in: PubMed
    Score: 0.023
  2. Using a Do-It-Yourself Artificial Pancreas: Perspectives from Patients and Diabetes Providers. J Diabetes Sci Technol. 2020 09; 14(5):860-867.
    View in: PubMed
    Score: 0.021
  3. The Impact of Biomarker Screening and Cascade Genetic Testing on the Cost-Effectiveness of MODY Genetic Testing. Diabetes Care. 2019 12; 42(12):2247-2255.
    View in: PubMed
    Score: 0.020
  4. Pediatric Monogenic Diabetes: A Unique Challenge and Opportunity. Pediatr Ann. 2019 Aug 01; 48(8):e319-e325.
    View in: PubMed
    Score: 0.020
  5. GCK-MODY in the US Monogenic Diabetes Registry: Description of 27 unpublished variants. Diabetes Res Clin Pract. 2019 May; 151:231-236.
    View in: PubMed
    Score: 0.019
  6. Economics of Genetic Testing for Diabetes. Curr Diab Rep. 2019 03 27; 19(5):23.
    View in: PubMed
    Score: 0.019
  7. Management and pregnancy outcomes of women with GCK-MODY enrolled in the US Monogenic Diabetes Registry. Acta Diabetol. 2019 Apr; 56(4):405-411.
    View in: PubMed
    Score: 0.019
  8. Monogenic Diabetes in Children and Adolescents: Recognition and Treatment Options. Curr Diab Rep. 2018 06 22; 18(8):58.
    View in: PubMed
    Score: 0.018
  9. Clinical Management of Women with Monogenic Diabetes During Pregnancy. Curr Diab Rep. 2018 02 15; 18(3):12.
    View in: PubMed
    Score: 0.018
  10. Adolescent non-adherence reveals a genetic cause for diabetes. Diabet Med. 2015 Jun; 32(6):e20-3.
    View in: PubMed
    Score: 0.015
  11. Cost-effectiveness of MODY genetic testing: translating genomic advances into practical health applications. Diabetes Care. 2014; 37(1):202-9.
    View in: PubMed
    Score: 0.013
  12. Who should have genetic testing for maturity-onset diabetes of the young? Clin Endocrinol (Oxf). 2011 Oct; 75(4):422-6.
    View in: PubMed
    Score: 0.011
  13. GLP-1 RA and dual GIP/GLP-1 RA treatment in MODY: a descriptive case series. BMJ Open Diabetes Res Care. 2025 Apr 23; 13(2).
    View in: PubMed
    Score: 0.007
  14. High Prevalence of A-ß+ Ketosis-Prone Diabetes in Children with Type 2 Diabetes and Diabetic Ketoacidosis at Diagnosis: Evidence from the Rare and Atypical Diabetes Network (RADIANT). Pediatr Diabetes. 2024; 2024.
    View in: PubMed
    Score: 0.007
  15. Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine. Nat Med. 2023 10; 29(10):2438-2457.
    View in: PubMed
    Score: 0.007
  16. Objective and Subjective Sleep Patterns in Adults With Maturity-Onset Diabetes of the Young (MODY). Diabetes Care. 2023 03 01; 46(3):608-612.
    View in: PubMed
    Score: 0.006
  17. Diagnosis, treatment and disclosure: A qualitative exploration of participant challenges in a Monogenic Diabetes Registry. Genet Med. 2023 04; 25(4):100019.
    View in: PubMed
    Score: 0.006
  18. Iatrogenic Hyperinsulinemia, Not Hyperglycemia, Drives Insulin Resistance in Type 1 Diabetes as Revealed by Comparison With GCK-MODY (MODY2). Diabetes. 2019 08; 68(8):1565-1576.
    View in: PubMed
    Score: 0.005
  19. Individualized Glycemic Control for U.S. Adults With Type 2 Diabetes: A Cost-Effectiveness Analysis. Ann Intern Med. 2018 02 06; 168(3):170-178.
    View in: PubMed
    Score: 0.004
  20. Hypoglycemia in sulfonylurea-treated KCNJ11-neonatal diabetes: Mild-moderate symptomatic episodes occur infrequently but none involving unconsciousness or seizures. Pediatr Diabetes. 2018 05; 19(3):393-397.
    View in: PubMed
    Score: 0.004
  21. Patients with KCNJ11-related diabetes frequently have neuropsychological impairments compared with sibling controls. Diabet Med. 2016 10; 33(10):1380-6.
    View in: PubMed
    Score: 0.004
  22. GCK-MODY in the US National Monogenic Diabetes Registry: frequently misdiagnosed and unnecessarily treated. Acta Diabetol. 2016 Oct; 53(5):703-8.
    View in: PubMed
    Score: 0.004
  23. Insulin dosing in pediatric diabetic ketoacidosis: where to start? JAMA. 2015 Jun 09; 313(22):2274-5.
    View in: PubMed
    Score: 0.004
  24. Age at the time of sulfonylurea initiation influences treatment outcomes in KCNJ11-related neonatal diabetes. Diabetologia. 2015 Jul; 58(7):1430-5.
    View in: PubMed
    Score: 0.004
  25. Sulfonylurea treatment before genetic testing in neonatal diabetes: pros and cons. J Clin Endocrinol Metab. 2014 Dec; 99(12):E2709-14.
    View in: PubMed
    Score: 0.004
  26. Neonatal diabetes: an expanding list of genes allows for improved diagnosis and treatment. Curr Diab Rep. 2011 Dec; 11(6):519-32.
    View in: PubMed
    Score: 0.003
  27. Creation of the Web-based University of Chicago Monogenic Diabetes Registry: using technology to facilitate longitudinal study of rare subtypes of diabetes. J Diabetes Sci Technol. 2011 Jul 01; 5(4):879-86.
    View in: PubMed
    Score: 0.003
  28. Neonatal diabetes mellitus: a model for personalized medicine. Trends Endocrinol Metab. 2010 Aug; 21(8):464-72.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.